Navigation Links
Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante

Martek Biosciences Corporation announced today that it has entered into a multi-year, sole-source supply agreement with Lactalis Nutrition Sante for the use of life'sARA™ in infant formulas and growing-up milks produced by Lactalis and sold in France and Algeria.

Columbia, MD (Vocus) May 14, 2009 - Martek Biosciences Corporation (NASDAQ: MATK) announced today that it has entered into a multi-year, sole-source supply agreement with Lactalis Nutrition Sante for the use of life'sARA™ in infant formulas and growing-up milks produced by Lactalis and sold in France and Algeria.

"Our partnership with Lactalis further demonstrates that companies worldwide understand the importance of adding Martek's ARA to infant formula for infant health and development," said Ethan Leonard, vice president of pediatric nutrition for Martek. "Martek's DHA and ARA can be found in infant formula sold in more than 75 countries, and we continue to expand our international presence in the infant formula market."

Naturally present in human breast milk, ARA (arachidonic acid) is a fatty acid important to infant development and growth. Clinical studies have demonstrated numerous benefits, including improved mental and visual development, for infants receiving infant formula supplemented with ARA and DHA (docosahexaenoic acid), another fatty acid important to infant development. Martek's blend of DHA and ARA, life'sDHA & life'sARA™, is the only source of these nutrients currently used in U.S. infant formula, and is present in more than 95 percent of infant formula sold in the U.S. Additionally, Martek is a leading global supplier of DHA and ARA and infant formulas containing Martek's nutritional oils are available in more than 75 countries worldwide.

Lactalis Nutrition Sante, a French company with a presence in over 40 countries, specializes in nutritional products in five areas: infant nutrition, oral clinical nutrition, enteral clinical nutrition, metabolic diseases, and gluten-free and allergen-free products.

Martek Biosciences Corporation is a leader in the innovation and development of DHA and ARA and has developed patented technology for the production and use of these ingredients. DHA omega-3 products promote health and wellness through every stage of life and ARA omega-6 products support growth and development in infants and children. The company produces life'sDHA™, a sustainable vegetarian source of DHA omega-3, for use in foods, beverages, infant formula and supplements, and life'sARA™, a sustainable vegetarian source of ARA omega-6, for use in infant formula and growing up milks. For more information on Martek Biosciences, visit For more information on products containing life'sDHA and life'sARA, visit

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Cassie France-Kelly
Public Relations
(443) 542-2116

Kyle Stults
Investor Relations
(410) 740-0081


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Martek Announces Third Quarter 2007 Financial Results
3. Martek Announces Addition of lifesDHA(TM) to Entire Bellybar(TM) Line of Nutrition Bars
4. Martek Signs Multi-Year Infant Formula License and Supply Agreement with Alter Farmacia
5. Marteks lifesDHA(TM) Featured in New Beech-Nut(R) DHA Plus Baby Food and Cereals
6. Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinovas Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements
7. Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International
8. Marteks lifesDHA(TM) Featured in Dalco Foods Wellness Line Meat Products
9. Martek Announces Settlement of Class Action Lawsuit
10. Pocket Rocket Juice from Australias Boost Juice Features 700 mg of Marteks lifesDHA(TM)
11. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
Post Your Comments:
Related Image:
Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante 
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: